Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The current state of recombinant allergens for immunotherapy

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Highlights in allergic contact dermatitis 2018/2019

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The impact of common metal allergens in daily devices

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Allergen-specific immunotherapy and risk of autoimmune disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Clinical update on contact allergy

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Subcutaneous immunotherapy is a well documented treatment of allergic rhinitis and asthma. The majority of the disadvantages of the treatment are related to the poor quality of the natural allergen extracts which can contain varying amounts of individual allergens including allergens to which the patient may not be sensitized. Recombinant allergens offer a possibility to use well defined molecules with consistent pharmaceutical quality defined in mass units. The proof of concept of the clinical efficacy of recombinant allergens is based on two studies published as full articles.
Original languageEnglish
JournalCurrent Opinion in Allergy and Clinical Immunology
Volume10
Issue number6
Pages (from-to)575-81
Number of pages7
ISSN1528-4050
DOIs
Publication statusPublished - 1 Dec 2010

ID: 32167064